H3 Biomedicine

H3 Biomedicine is a privately held, uniquely structured oncology discovery enterprise. At H3, they seek to become a prolific source of new drugs that treat more human cancers with greater success. H3 Biomedicine is applying the expertise of leading scientists to the integration of insights from cancer genomics with innovative capabilities in synthetic chemistry and tumor biology to pursue patient-based, genomics-driven, small molecule drugs, which represent the most promising current opportunity in cancer therapeutics.